Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab Preemptive Treatment in MCL Molecular Relapse
NCT03229382Phase 2Terminated
- Sponsor
- Polish Lymphoma Research Group
- Start
- May 2018
- Primary completion
- Jan 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of obinutuzumab in mantle cell lymphoma (MCL), sponsored by Polish Lymphoma Research Group. Started May 2018; status: terminated.
02
Drugs
obinutuzumab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03229382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03229382.